Woodline Partners LP Denali Therapeutics Inc. Transaction History

Woodline Partners LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $6.76 Million - $10.5 Million	-452,011 Reduced 88.88%	56,554 $1.31 Million
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $4.92 Million - $7.26 Million	310,981 Added 157.39%	508,565 $10.4 Million
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $10.6 Million - $15.2 Million	-653,905 Reduced 76.8%	197,584 $4.24 Million
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $15.3 Million - $22.3 Million	739,277 Added 658.82%	851,489 $17.6 Million
Q2 2023 Aug 14, 2023	BUY	$23.37 - $32.96 $278,126 - $392,256	11,901 Added 11.86%	112,212 $3.31 Million
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $2.2 Million - $3.28 Million	100,311 New	100,311 $2.31 Million
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $6.84 Million - $10.1 Million	263,284 Added 145.48%	444,256 $13.6 Million
Q2 2022 Aug 15, 2022	SELL	$20.88 - $35.19 $1.58 Million - $2.66 Million	-75,706 Reduced 29.49%	180,972 $5.33 Million
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $5.92 Million - $9.65 Million	204,224 Added 389.34%	256,678 $8.26 Million
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $2.23 Million - $2.89 Million	52,454 New	52,454 $2.34 Million

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.